Medical

controlled release

Also found in: Dictionary, Legal, Financial, Acronyms, Encyclopedia, Wikipedia.
(redirected from Sustained release)

con·trolled re·lease

(kŏn-trōld rĕ-lēs)
Delivery of a chemotherapeutic agent to a site-specific area. The agent is released from the carrier device at a fixed rate (e.g., by a dermal patch or a polymeric fiber, such as that used to deliver a therapeutic agent to a periodontal pocket).
Medical Dictionary for the Dental Professions © Farlex 2012
Mentioned in
References in periodicals archive
The application of lipids in sustained release formulations is a growing area of interest.
The sustained release form stays in the body longer for extended absorption, higher muscle retention to extend endurance, speed muscle recovery, build muscle strength and enhance peak performance capabilities.
According to the company, DEXTENZA (sustained release dexamethasone) Intracanalicular Depot is placed through the punctum, a natural opening in the eyelid, into the canaliculus and is designed to deliver dexamethasone to the ocular surface for four weeks.
Pharmaceutical company Alimera Sciences (NasdaqGM:ALIM) revealed on Tuesday the launch of an exclusive agreement for the distribution in Canada of its sustained release intravitreal implant for the treatment of diabetic macular edema, ILUVIEN.
According to the company, its innovative TransCon technology combines the benefits of prodrug and sustained release technologies to develop a pipeline of best-in-class therapeutics that address significant unmet medical needs.
The company's range of issued patents and patent applications now includes the release formulations and pharmacokinetic profile of Metadoxine, including the special sustained release, combined release and burst release formulations and the associated methods of treatment, and the clinical utilisation of MDX for cognitive disorders including Alcobra's lead indication, ADHD.
Following this second patent in the US covering MDX, the company's portfolio of issued patents and patent applications now covers the release formulations and pharmacokinetic profile of Metadoxine, the special sustained release, combined release and burst release formulations and the associated methods of treatment, as well as the clinical utilisation of MDX.
Copyright © 2003-2025 Farlex, Inc Disclaimer
All content on this website, including dictionary, thesaurus, literature, geography, and other reference data is for informational purposes only. This information should not be considered complete, up to date, and is not intended to be used in place of a visit, consultation, or advice of a legal, medical, or any other professional.